SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/211432"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/211432" > PR3-ANCA: A Promisi...

PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)

Stinton, L. M. (författare)
Bentow, C. (författare)
Mahler, M. (författare)
visa fler...
Norman, G. L. (författare)
Eksteen, B. (författare)
Mason, A. L. (författare)
Kaplan, G. G. (författare)
Lindkvist, Björn (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
Hirschfield, G. M. (författare)
Milkiewicz, P. (författare)
Cheung, A. (författare)
Janssen, H. L. A. (författare)
Fritzler, M. J. (författare)
visa färre...
 (creator_code:org_t)
 
visa fler...
 
visa färre...
2014
2014
Engelska.
Ingår i: Plos One. - 1932-6203. ; 9:11
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background and Aims: The only recognized biomarker for primary sclerosing cholangitis (PSC) is atypical anti-neutrophil cytoplasmic antibodies (aANCA), which, in addition to having low sensitivity and specificity, is an indirect immunofluorescence (IIF) test lacking the advantages of high throughput and objectivity. Recent reports have shown that antibodies to proteinase-3 (PR3-ANCA) might add diagnostic value in inflammatory bowel disease (IBD), specifically in ulcerative colitis (UC). As PSC is associated with IBD, the objective of this study was to evaluate the frequency and clinical significance of PR3-ANCA in a large cohort of patients. Methods: A total of 244 PSC and 254 control [autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), hepatitis C viral infection (HCV), hepatitis B viral infection (HBV), and healthy controls] sera and their clinical correlations were retrospectively analyzed for PR3-ANCA determined by ELISA and a new chemiluminescence immunoassay (CIA). Testing was also performed for aANCA by IIF. Results: When measured by CIA, PR3-ANCA was detected in 38.5% (94/244) of PSC patients compared to 10.6% (27/254) controls (p<0.0001). By ELISA, PR3-ANCA was detected in 23.4% (57/244) of PSC patients compared to 2.7% (6/254) controls (p<0.0001). PR3-ANCA in PSC patients was not associated with the presence or type of underlying IBD, and, in fact, it was more frequent in Crohn's disease (CD) patients with PSC than previously reported in CD alone. PR3-ANCA in PSC measured by CIA correlated with higher liver enzymes. Conclusion: PR3-ANCA is detected in a significant proportion of PSC patients compared to other liver diseases including PBC and AIH. PR3-ANCA is associated with higher liver enzyme levels in PSC, and is not solely related to underlying IBD.

Nyckelord

ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES
INTERNATIONAL CONSENSUS
STATEMENT
INFLAMMATORY-BOWEL-DISEASE
ULCERATIVE-COLITIS
AUTOIMMUNE
HEPATITIS
LIVER-DISEASE
TREATED VASCULITIS
TARGET ANTIGENS
MPO-ANCA
AUTOANTIBODIES
Multidisciplinary Sciences

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • Plos One (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy